Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + daratumumab + low-dose dexamethasone in unfit or frail newly diagnosed multiple myeloma
NL-OMON23842Active, not recruiting
- Sponsor
- HOVON
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of ixazomib, daratumumab and dexamethasone, sponsored by HOVON. Started Jun 2017; status: active, not recruiting.
02
Drugs
ixazomibdaratumumabdexamethasone
Beyond the preview
Go deeper on NL-OMON23842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23842.